Natera and Incyte Announce Clinical Collaboration for Phase II Colorectal Cancer Study
Natera and Incyte have entered into a clinical collaboration agreement to evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in a new Phase II study for patients with stage 2/3 colorectal cancer.